Branded Bevacizumab Approved for Wet AMD

MedPage Today

(MedPage Today) -- The FDA approved the first formulation of bevacizumab specifically for the treatment of neovascular (wet) age-related macular degeneration (nAMD), Outlook Therapeutics announced on Friday.
The approval of bevacizumab-vikg (Lytenava...

전문 보기

이 뉴스, 어떠셨어요?

탭 한 번으로 반응 · 로그인 불필요

Branded Bevacizumab Approved for Wet AMD

이 뉴스, 어떠셨어요?

관련 뉴스

'science' 카테고리 뉴스

Prize honors discovery of altermagnetism as a third fundamental class of magnetism

Rates of opioid toxicity deaths highest among construction and trades workers, study finds

SpaceX's Starship megarocket makes the 'softest splashdown' ever after launching next-gen Starlink satellites in Flight 13 test (video)

MedPage Today의 다른 기사

FDA Panel Finds a Peptide It Doesn't Like

New Avacopan Analysis Sent to FDA After Data Manipulation Allegations

FDA Approves Tylenol With Naproxen Combination